Odyssey Therapeutics, Inc., a US-based biotechnology company, announced on Tuesday that it has named Darryl Patrick, DVM., PhD as its new executive vice president of Non-Clinical Development.

Dr Patrick has over 30 years of experience in non-clinical development, including senior leadership roles at Vertex Pharmaceuticals and Merck Research Laboratories. He has served as partner and acted as a non-clinical development consultant for numerous companies globally across a range of therapeutic categories including antibodies, fusion proteins, as well as small molecules for the treatment of cancer, anti-inflammatory therapies, and autoimmune disease at LionsKeep Associates. He started his career in Veterinary Medicine with the US Air Force, becoming chief of Diagnostic and Comparative Medicine for the Uniformed Services, University of Health Sciences.

Gary D Glick, Ph.D., Odyssey Therapeutics founder and chief executive officer, said, 'Darryl's leadership in non-clinical development and experience bringing dozens of development candidates, including small molecules, proteins, along with gene therapies through the preclinical process will prove invaluable to Odyssey as we advance our portfolio of immunology and oncology medicines into clinical studies. I'm excited to welcome Darryl to accelerate the development pathway for transformative medicines and provide hope for patients in need.'